IPO - GLENMARK LIFE SCIENCES LIMITED

IPO - GLENMARK LIFE SCIENCES LIMITED

Glenmark Life Sciences Limited :

 

IMPORTANT DATA:

 

IPO issue opens on	27.07.2021
Closes on	29.07.2021
Listing in	BSE and NSE
Issue Type	Book Built Issue IPO
Issue Size	Aggregating upto Rs. 1513.60 crores
Fresh Issue	Aggregating upto Rs. 1060.00 crores
Offer for Sale	Rs. 453.60 crores of 63,00,000 Equity Shares
Issue Price	Rs. 695/- – Rs. 720/- per Equity Share
Face Value	Rs. 2/- per Equity Share
Application/Share	Rs. 695/-to Rs. 720/-  per Equity Share
Minimum Bid Qnty. (Min. Lot size)	20 Equity Shares of One Lot
Minimum amount required to apply	Rs. 14,400/- per Lot
Maximum Bid Qnty. For Retail Investors (Max. Lot size)	13 Lots of 20 Equity Shares = 260 Shares
Maximum amount required to apply	Rs. 1,87,200/-
Face Value	Rs. 2/- per Equity Share
Registrar of Issue	KFin Technologies Pvt. Ltd.
Objectives of IPO	To pay the outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company, which is in pursuant of the Agreement dated 9.10.2018(Rs. 800 crores). To meet with the capital expenditure requirements to the tune of Rs. 152.76 crores. To meet general corporate purposes.
Basis of Allotment	Type % of Offer Allotment Basis Qualified Institutional Buyers 50 Roughly Equivalent Non Institutional Investors 15 As above Retail Investors 35 Minimum of 1 lot depending upon the availability

 

IMPORTANT TIMELINE TO NOTE:

 

Open Date	27.07.2021
Offer Close Date	29.07.2021
Basis of Allotment Date	03.08.2021
Refund Starts from (will be initated from)	04.08.2021
Credited to Demat Account	05.07.2021
Listing on BSE and NSE	06.07.2021

 

BRIEF PROFILE OF THE COMPANY :

 

·       Glenmark Life Sciences Limited, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited was established in the year 2011.

 

·       Following the spin-off, the company operates as an independent, professionally-managed global API business.

 

·       The IPO Company is one of the leading manufacturers of Active Pharmaceutical Ingredients (API).

 

·       The APIs include chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes, as per Frost & Sullivan report. It also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas.

 

·       The Company has its export business to many countries in Europe, North America, Latin America, Japan and other parts of the Globe.

 

·       The company plans to enhance its API manufacturing capability at Ankleshwar Unit during the Financial Year 2022 and also in their Dahej facility during the next year and Financial Year 2023.

 

·       The company has been maintaining a good relationship with many leading Global Generic Companies.

 

·       The Company has four manufacturing facilities in Ankleshwar and Dahej in Gujarat and Mohol and Kurkumb in Maharashtra with annual installed capacity of 725.80 KL as of December, 2020.

 

·       The Company is having proven record of high level financial strength.

 

·       Total assets of the Company which stood at Rs. 0.09 crores in 2018, increased to Rs. 1475.40 crores as of FY 2019 and rose to Rs. 1725.60 crores and further went upto Rs. 1956.57 crores as of 31.03.2021.

 

·       Similarly, the Total Income was Rs. 886.87 crores in March, 2019 and furthered upto Rs. 1549.30 crores in March, 2020 and stood at a level of Rs. 1885.98 crores for the FY ended 31.03.2021.

 

·       Likewise, the PAT (Profit After Tax) increased from Rs. 195.59 crores in March, 2019 to  Rs. 313.10 crores as of March, 2020 and reached a level of Rs. 351.58 crores in FY 2021.

 

 

Promoters and Management:

 

Shri Glenn Saldanha	Chairman and non-executive director
Shri VS Mani	Non-Executive Director
Yasir Rawjee	Managing Director and Chief Executive Officer
Sumantra Mitra	Executive Director and Vice President – Human Resources Department
Sridhar Gorthi	Independent Director
Manju Agarwal	Independent Director
Taruvai Laxminarayanan Easwar	Independent Director
Gita Nayyar	Independent Director
Bhavesh Pujara	Senior Vice President and Chief Financial Officer

 

                                   

 

STRENGTH OF THE COMPANY:

1.               Well experienced in the line of activity

2.               Experienced Promoters

3.               The Company has established Global Market.

4.               Proven YoY Financial growth

 

HOW TO APPLY:

 

1.         Login to your Broker’s Website

2.         Search for IPO Tab

3.         Enter the details

4.         Submit

5.         Ensure that adequate Balance is available in your Account to meet with the debits   for IPO.

 

You can also apply through ASBA of your Bank’s Internet Banking portal, if you have netbanking facility.